JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.4
13.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
JiangSu WuZhong Pharmaceutical Development Co Ltd
JiangSu WuZhong Pharmaceutical Development Co Ltd
Accrued Liabilities
JiangSu WuZhong Pharmaceutical Development Co Ltd
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
JiangSu WuZhong Pharmaceutical Development Co Ltd
SSE:600200
|
Accrued Liabilities
¥25.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-1%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Accrued Liabilities
¥2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Accrued Liabilities
¥620.1m
|
CAGR 3-Years
8%
|
CAGR 5-Years
39%
|
CAGR 10-Years
35%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Accrued Liabilities
¥128.5m
|
CAGR 3-Years
456%
|
CAGR 5-Years
130%
|
CAGR 10-Years
63%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Accrued Liabilities
¥1.5B
|
CAGR 3-Years
48%
|
CAGR 5-Years
46%
|
CAGR 10-Years
59%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Accrued Liabilities
¥146m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
JiangSu WuZhong Pharmaceutical Development Co Ltd
Glance View
Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. engages in the research and development, production and sales of pharmaceuticals, organic pigments, dyes and their intermediates. The company is headquartered in Suzhou, Jiangsu and currently employs 1,067 full-time employees. The firm's business includes pharmaceuticals, chemicals and real estate. Pharmaceutical business mainly involves pharmaceutical research, development, manufacture and sales. Chemical business mainly includes research, development, manufacture and sales of organic pigments, dyes and intermediates. Its main production varieties are used to produce reactive dyes and organic pigments. Real estate business includes commercial housing and affordable housing.
See Also
What is JiangSu WuZhong Pharmaceutical Development Co Ltd's Accrued Liabilities?
Accrued Liabilities
25.8m
CNY
Based on the financial report for Sep 30, 2024, JiangSu WuZhong Pharmaceutical Development Co Ltd's Accrued Liabilities amounts to 25.8m CNY.
What is JiangSu WuZhong Pharmaceutical Development Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
-1%
Over the last year, the Accrued Liabilities growth was 38%. The average annual Accrued Liabilities growth rates for JiangSu WuZhong Pharmaceutical Development Co Ltd have been 12% over the past three years , 11% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
